allow individualized investigative treatments for patients with life-threatening or debilitating diseases or conditions.
What changed between versions
Added new definitions for 'eligible facility,' 'eligible patient,' 'general investigative treatment,' 'individualized investigative treatment,' and 'physician' to clarify who can access these treatments.
Established specific criteria for patient eligibility including having a life-threatening condition, considering all FDA-approved options, receiving physician recommendation, and providing informed consent.
Created detailed informed consent requirements including written documentation explaining current treatment options, potential outcomes, insurance implications, and hospice care considerations.
Established that manufacturers cannot seek reimbursement from patient estates if the patient dies while receiving the treatment.
Clarified that patient health insurance is not obligated to pay for these treatments and patients are liable for all associated expenses.
Added protections preventing license revocation for physicians recommending these treatments and prohibiting state officials from blocking patient access.
